Daniel Ebner
Professor - Principal Investigator in Cellular High Throughput Screening
Daniel Ebner is an Associate Professor and Principal Investigator at the University of Oxford and heads the TDI High Throughput Cellular Screening Facility and the Oxford CRISPR/Cas9 Screening Facility at the Target Discovery Institute (TDI), Centre for Medicines Discovery, Nuffield Department of Medicine. Daniel’s main academic research, through a five year £7M CRUK funded grant in collaboration with researchers from the University of Edinburgh and MIT, is focused on identifying and advancing novel combinatorial therapeutics for the treatment of glioblastoma. As head of the cellular screening facility, Daniel has worked with academic and industrial collaborators to complete >150 research projects and has published >70 peer-reviewed papers in the past 5 years in high impact journals such as the Lancet, New England Journal of Medicine, Nature and Journal of the American Medical Association across a broad range of pathologies including on neurodegeneration, inflammation, autophagy, large-scale iPSC CRISPR/Cas9 screening methods, and novel more physiologically relevant screening models. Previous to his academic career at the University of Oxford, Daniel has worked for >10 years in the biotechnology and pharmaceutical industry.
Recent publications
-
Reduction of Z alpha-1 antitrypsin polymers in human iPSC-hepatocytes and mice by LRRK2 inhibitors.
Journal article
Kent D. et al, (2024), Hepatology
-
Improving the representativeness of UK's national COVID-19 Infection Survey through spatio-temporal regression and post-stratification.
Journal article
Pouwels KB. et al, (2024), Nat Commun, 15
-
Targeting NKG2D ligands in glioblastoma with a bispecific T-cell engager is augmented with conventional therapy and enhances oncolytic virotherapy of glioma stem-like cells.
Journal article
Baugh R. et al, (2024), J Immunother Cancer, 12
-
Optimized protocol for CRISPR knockout of human iPSC-derived macrophages.
Journal article
Navarro-Guerrero E. et al, (2024), STAR Protoc, 5
-
Author Correction: C16orf72/HAPSTR1/TAPR1 functions with BRCA1/Senataxin to modulate replication-associated R-loops and confer resistance to PARP disruption.
Journal article
Sharma AB. et al, (2023), Nat Commun, 14